Navigation Links
Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its phase II/III RAPID trial comparing CHOP-R to CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R, in first-line treatment of patients with aggressive non-Hodgkin's lymphoma.

                           Conference Call Numbers

                              Wednesday, July 11

       1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European

                       1-800-240-7305 (US Participants)

                        1-303-262-2137 (International)


                            Live audio webcast at

                             www.cticseattle.com

                     will be archived for post listening

       approximately two hours after call ends, available for five days


     Call-back numbers for post listening available at 6:30 p.m. Eastern:

                       1-800-405-2236 (US Participants)

                        1-303-590-3000 (International)

                             Passcode: 11093505#


     Media Contact:


     Cell Therapeutics, Inc.

     Dan Eramian

     T: 206.272.4343

     C: 206.854.1200

     Susan Callahan

     T: 206.272.4472

     F: 206.272.4434

     E: 

     www.cticseattle.com/media.htm


     Investors Contact:


     Cell Therapeutics, Inc.

     Leah Grant

     T: 206.282.7100

     F: 206.272.4434

     E: 

     www.cticseattle.com/investors.htm

media@ctiseattle.com invest@ctiseattle.com

CONTACT: media, Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or, or investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4434, or , all for Cell Therapeutics, Inc. media@ctiseattle.com invest@ctiseattle.com

Web site: http://www.cticseattle.com//

Ticker Symbol: (NASDAQ-NMS:CTIC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
2. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
3. Choosing Lab Quality Management Software
4. Optimizing Quality Control Data Management
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
7. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
8. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
11. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2020)... ... June 25, 2020 , ... Billon Group ... build a distributed ledger platform to store COVID-19 related certificates to support workers’ ... a fully functioning prototype for publishing, sharing and verifying a wide array of ...
(Date:6/25/2020)... ... June 25, 2020 , ... The FSHD Society ... , which is being conducted entirely online for the first time in the ... the discussion and dissemination of state-of-the-art research on facioscapulohumeral muscular dystrophy (FSHD). A ...
(Date:6/24/2020)... Va. (PRWEB) , ... June 24, 2020 , ... The ... sober this Fourth of July. Boating under the influence, or BUI, is the leading ... July 4 holiday is around the corner, and unfortunately has become known for drinking ...
Breaking Medicine Technology:
(Date:7/4/2020)... ... July 03, 2020 , ... Houston Life coach, Rashad Garrett, has thrown a ... the launch of his new app, Faith Of A Mustard Seed (FOAMS). , The ... mental health issues. In fact, a Federal Agency emergency helpline dedicated to helping people ...
(Date:7/2/2020)... ... 2020 , ... Temprian, a spinoff from Northwestern University, has ... indication is vitiligo. Vitiligo patients develop progressive depigmentation of the skin. There is ... equally prevalent in all ethnic groups, it is most visible and impactful in ...
(Date:7/2/2020)... ... July 02, 2020 , ... Columbia Southern University (CSU), a ... Award to Eric Simmons of Temecula, California. , CSU’s occupational safety and ... a master’s degree in occupational safety and health from the university, is the ...
(Date:7/2/2020)... SHELTON, Conn. (PRWEB) , ... July 02, 2020 ... ... closure of many businesses, including dental offices for non-emergency work. In conjunction with ... released reopening guidelines for Connecticut dental practices in mid-May. , Due to ...
(Date:7/1/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... of cannabis and botanically-derived terpenes, has officially released its new terpene infused ... brands a way for consumers to enjoy cannabis terpene profiles and flavors worldwide. ...
Breaking Medicine News(10 mins):